Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York …

A Saxena, AJ Engel, B Banbury, G Hasan… - The Lancet …, 2022 - thelancet.com
anti-rheumatic drugs (DMARDs) is not only associated with suppression of active
inflammation, but also allows the repair of initial joint damage. However, little is known about …

Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases

R Felten, M Dubois, MF Ugarte-Gil… - The Lancet …, 2021 - thelancet.com
Vaccination is an important and effective tool to prevent infections in the general population,
as well as in patients with autoimmune and inflammatory rheumatic diseases. It has been …

First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection

L Perrot, M Hemon, JM Busnel, O Muis-Pistor… - The Lancet …, 2021 - thelancet.com
Comment www. thelancet. com/rheumatology Vol 3 January 2021 e7 before the onset of
clinical symptoms; and the presence of human leukocyte anti gen (HLA)-DR alleles that …

[HTML][HTML] Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome

RL Hoiland, S Stukas, J Cooper, S Thiara… - British Journal of …, 2020 - ncbi.nlm.nih.gov
Coronavirus disease 2019 (COVID-19) severity appears to parallel the host immune
response, with a subset of patients developing COVID-19 cytokine storm syndrome (CSS). 1 …

Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases

J Teng, J Dai, Y Su, Z Zhou, H Chi, L Wan… - The Lancet …, 2020 - thelancet.com
In December, 2019, an outbreak of the novel coronavirus (SARS-CoV-2) that causes
coronavirus dis ease 2019 (COVID-19) occurred in Wuhan, China, 1 and soon spread all …

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

L Boekel, F Hooijberg, YR Besten… - The Lancet …, 2022 - thelancet.com
Before the global distribution of COVID-19 vaccines, we observed substantial concerns
among nonimmunocompromised people about the lack of longterm research or the …

Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

DP Misra, V Agarwal, AY Gasparyan, O Zimba - Clinical rheumatology, 2020 - Springer
The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …

Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?

G Zizzo, PL Cohen - The Lancet Rheumatology, 2020 - thelancet.com
The unique cytokine signature of COVID-19 might provide clues to disease mechanisms and
possible future therapies. Here, we propose a pathogenic model in which the alarmin …

SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study

D Saadoun, M Vieira, M Vautier… - The Lancet …, 2021 - thelancet.com
Background The COVID-19 pandemic has raised numerous questions among patients with
immune-mediated inflammatory diseases regarding potential reciprocal effects of COVID-19 …

[HTML][HTML] Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

R Felten, F Gallais, C Schleiss, E Chatelus… - The Lancet …, 2022 - ncbi.nlm.nih.gov
Humoral and cell-mediated immune responses are blunted after SARS-CoV-2 vaccination in
patients with a history of CD20 B-cell-depleting treatment. 1 However, vaccination induces …